These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 36890013)

  • 1. Increase in skeletal muscle extracellular volume as an under-recognised change detected at cardiac MRI in hypertrophic cardiomyopathy.
    Xu P; Liu W; Qian W; Wang J; Wang Y; Zhou X; Zhu Y; Xu Y; Zhu X
    Clin Radiol; 2023 May; 78(5):e401-e408. PubMed ID: 36890013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative diffusion-weighted magnetic resonance imaging in the assessment of myocardial fibrosis in hypertrophic cardiomyopathy compared with T1 mapping.
    Wu LM; Chen BH; Yao QY; Ou YR; Wu R; Jiang M; Hu J; An DA; Xu JR
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1289-97. PubMed ID: 27198892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of Myocardial Fibrosis Parameters Derived from Cardiac Magnetic Resonance Imaging in Risk Stratification for Patients with Hypertrophic Cardiomyopathy.
    Yu T; Cai Z; Yang Z; Lin W; Su Y; Li J; Xie S; Shen J
    Acad Radiol; 2023 Sep; 30(9):1962-1978. PubMed ID: 36604228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy.
    Thompson EW; Kamesh Iyer S; Solomon MP; Li Z; Zhang Q; Piechnik S; Werys K; Swago S; Moon BF; Rodgers ZB; Hall A; Kumar R; Reza N; Kim J; Jamil A; Desjardins B; Litt H; Owens A; Witschey WRT; Han Y
    J Cardiovasc Magn Reson; 2021 Oct; 23(1):120. PubMed ID: 34689798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion-weighted imaging in hypertrophic cardiomyopathy: association with high T2-weighted signal intensity in addition to late gadolinium enhancement.
    Shi RY; An DA; Chen BH; Wu R; Du L; Jiang M; Xu JR; Wu LM
    Int J Cardiovasc Imaging; 2020 Nov; 36(11):2229-2238. PubMed ID: 32666169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial fibrosis evaluated by diffusion-weighted imaging and its relationship to 3D contractile function in patients with hypertrophic cardiomyopathy.
    Wu R; An DA; Shi RY; Chen BH; Jiang M; Bacyinski A; Han TT; Hu J; Xu JR; Wu LM
    J Magn Reson Imaging; 2018 Oct; 48(4):1139-1146. PubMed ID: 29601139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.
    Xu J; Zhuang B; Sirajuddin A; Li S; Huang J; Yin G; Song L; Jiang Y; Zhao S; Lu M
    Radiology; 2020 Feb; 294(2):275-286. PubMed ID: 31769741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial extracellular volume fraction measurements with MOLLI 5(3)3 by cardiovascular MRI for the discrimination of healthy volunteers from dilated and hypertrophic cardiomyopathy patients.
    Cui Y; Chen Y; Cao Y; Liu J; Song J; Zhang S; Kong X; Han P; Shi H
    Clin Radiol; 2019 Sep; 74(9):732.e9-732.e16. PubMed ID: 31122714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy.
    Ho CY; Abbasi SA; Neilan TG; Shah RV; Chen Y; Heydari B; Cirino AL; Lakdawala NK; Orav EJ; González A; López B; Díez J; Jerosch-Herold M; Kwong RY
    Circ Cardiovasc Imaging; 2013 May; 6(3):415-22. PubMed ID: 23549607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous assessment of late gadolinium enhancement grey zone in patients with non-ischaemic cardiomyopathy with T1ρ and native T1 mapping.
    Dong Z; Yin G; Yang K; Jiang K; Wu Z; Chen X; Song Y; Yu S; Wang J; Yang S; Ma X; Xu Y; Zhao K; Lu M; Xu X; Zhao S
    Eur Heart J Cardiovasc Imaging; 2023 Mar; 24(4):492-502. PubMed ID: 35793269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histogram Analysis of Native T
    Wu CW; Wu R; Shi RY; An DA; Chen BH; Jiang M; Bacyinski A; Rahim A; Deen JM; Hu J; Han TT; Xu JR; Wu LM
    J Magn Reson Imaging; 2019 Mar; 49(3):668-677. PubMed ID: 30142234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncontrast T1ρ dispersion imaging is sensitive to diffuse fibrosis: A cardiovascular magnetic resonance study at 3T in hypertrophic cardiomyopathy.
    Wang K; Zhang W; Li S; Jin H; Jin Y; Wang L; Li R; Yang Y; Zheng J; Cheng J
    Magn Reson Imaging; 2022 Sep; 91():1-8. PubMed ID: 35525524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.
    Urbano-Moral JA; Rowin EJ; Maron MS; Crean A; Pandian NG
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):11-9. PubMed ID: 24275954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy.
    Li Y; Liu X; Yang F; Wang J; Xu Y; Fang T; Pu L; Zhou X; Han Y; Chen Y
    Eur Radiol; 2021 Jul; 31(7):4557-4567. PubMed ID: 33449190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T1 mapping in children and young adults with hypertrophic cardiomyopathy.
    Parekh K; Markl M; Deng J; de Freitas RA; Rigsby CK
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):109-117. PubMed ID: 27659477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of late gadolinium enhancement in hypertrophic cardiomyopathy: comparison of diagnostic performance in myocardial fibrosis between gadobutrol and gadopentetate dimeglumine.
    Liu D; Ma X; Liu J; Zhao L; Chen H; Xu L; Sun Z; Fan Z
    Int J Cardiovasc Imaging; 2017 Aug; 33(8):1191-1200. PubMed ID: 28289991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy.
    Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between myocardial hypoxia and fibrosis in hypertrophic cardiomyopathy: analysis by T2* BOLD and T1 mapping MRI.
    Ando K; Nagao M; Watanabe E; Sakai A; Suzuki A; Nakao R; Ishizaki U; Sakai S; Hagiwara N
    Eur Radiol; 2020 Aug; 30(8):4327-4336. PubMed ID: 32211964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Native T1-mapping for non-contrast assessment of myocardial fibrosis in patients with hypertrophic cardiomyopathy--comparison with late enhancement quantification.
    Małek ŁA; Werys K; Kłopotowski M; Śpiewak M; Miłosz-Wieczorek B; Mazurkiewicz Ł; Petryka-Mazurkiewicz J; Marczak M; Witkowski A
    Magn Reson Imaging; 2015 Jul; 33(6):718-24. PubMed ID: 25863138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of the estimated 5-year risk of sudden cardiac death and syncope or non-sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy using late gadolinium enhancement and extracellular volume CMR.
    Avanesov M; Münch J; Weinrich J; Well L; Säring D; Stehning C; Tahir E; Bohnen S; Radunski UK; Muellerleile K; Adam G; Patten M; Lund G
    Eur Radiol; 2017 Dec; 27(12):5136-5145. PubMed ID: 28616729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.